

TAKE2 PROPHECY TEST FOR NASOPHARYNGEAL CANCER

ACCURACY

GO

Are you at risk of nasopharyngeal cancer

Its incidence in Hong Kong is 5 to 6 times the world's average¹²!

What is NPC?

Nasopharyngeal cancer (NPC) is a type of head and neck cancer which originates in the nasopharynx. The nasopharynx is located at the "concealed" area between the middle of the head, at the end of the nasal cavity, and the upper part of the throat

Common symptoms of NPC include the following:





Nasal blockage (ringing sound in the ear)



(a)

Vosebleed



NPC is also named the "Guangdong cancer"!

NPC, also known as "Guangdong cancer", has a particularly high incidence rate in Southeast Asia and Southern China, especially in Guangdong and Guangxi provinces and Hong Kong. In Hong Kong, NPC is one of the top ten cancers, and there are 600-800 new cases every year. It is also one of the top five cancers for men aged between 45-64 in the past ten years³

KEY FACTS ABOUT NPC

Are younger age men at lower risk of NPC?

In fact, NPC is the top cancer for men aged between 20-44⁴.





Is NPC affecting the males only?

NPC is one of the cancers that is more likely to occur between 50 to 60 years old in women, apart from breast cancer and uterine cancer³.

Ladies in their 20s can also be diagnosed with NPC*!

Women should not overlook the risk of getting NPC even at a younger age.

A real case was reported in a newspaper. A young lady was impacted seriously on her daily life due to the side effects of NPC treatment. She experienced swallowing difficulties and change in eating habits.

*Source: (Translated) "Cancer patients are prone to oral side effects after treatment, two fifths of them feel rusty in their mouths", HK01, 11 May 2021.

Is NPC an elderly disease?

>80% NPC patients are below the age of 65³.

60%

stage⁵.

One-sided / partial headache Facial numbness Double vision / abnormal eye movements Hearing loss Swallowing difficult Blood-stained nasal discharge

Age Distribution of Nasopharyngeal Cancer Incidence in Hong Kong 2009-2018³



Are the signs of early NPC easily identified?

As the symptoms of early NPC resemble flu or inflammatory illnesses (refer to the graph below), it is usually hard for patients to relate the symptoms to NPC at the early stage, causing a delay in seeking medical intervention. Research shows that 80% of unscreened patients were diagnosed with NPC at a late



Symptoms differ from person to person. Please consult healthcare professionals for details.

Is family history the only risk factor for NPC?

Family history is one of the factors⁶, but your daily habits and other external factors do matter as well!









fection with Epstein-Barr Virus (EBV)7





Frequent exposure to other carcinogens⁷

Be alert! Having exposure to multiple risk factors can make you more likely to develop NPC.

re you able to protect yourself ainst NPC without a vaccine?

he symptoms of NPC at an early stage are non-spe d not easy to be identified. There is no vaccine to prev nd no specific medication to cure NPC. Early detection e key to make a difference.

ents can be identified at the early stage, which enable elv treatment. NPC patients might have less treatm ly-stage NPC patients could be higher than 90%[°].

Get tested! The earlier you know, the better you can manage

Take2 Prophecy[™] **Test for Nasopharyngeal** Cancer

ake2 Prophecy™ Test for Nasopharyngeal Cancer is a groun eaking, blood-based, and non-invasive early cancer detection est. It analyses human and NPC-associated genomic signature of EBV DNA in the blood plasma using a combination olymerase Chain Reaction (PCR) and Next-generation quencing (NGS) technologies. It enables NPC patients to be itified in their early stage for timely treatment and increase heir survival rate.



Characteristics of the Take2 Prophecy™ Test for Nasopharyngeal Cancer



The test utilises the NGS technology invented by the world-class research team from The Chinese by синк University of Hong Kong (CUHK)



Sensitivity greater than 97%^{5,10}, fewer cases of NPC are missed; very low false-positive rate (0.7%)¹⁰



Simple and non-invasive, only requires a single blood draw without admission into the hospital

Adopted by numerous renowned medical institutions, you can even locate the nearest Widely accessible clinics and book an appointment online

The utilised technologies have been validated in a large-scale clinical study involving 20,000 Clinically individuals

How does Take2 Prophecy[™] Test compare with traditional EBV tests?

	Take2 Prophecy™ Test for Nasopharyngeal Cancer
Technology	PCR and NGS
Detection target	✓ Human and NPC- associated genomic signatures of EBV DNA
False positive rate	√ 0.7% ¹⁰
Sensitivity	✓>97% ^{5,10}
Validated for early NPC detection with large-scale clinical trial ⁵	~

Doctor consultation



1) Follow-up consultation with Ear. Nose & Throat Specialists if the test result is positive* 2) Regular check-ups if the test result is negative** Positive: Human and NPC-associated genomic signatures of EBV DNA were detected. Please consult healthcare professionals for more information. *Negative: Human and NPC-associated genomic signatures of EBV DNA were not detected. Please consult healthcare professionals for more information.

Traditional EBV DNA test	Traditional EBV serology tests
PCR only	Enzyme-linked immunosorbent assay (ELISA)
EBV DNA	Antibody of EBV (eg: IgA-VCA)
~3.4% ¹¹	Can be up to 40% ^{11,12}
~81.4% ¹¹	42.9-92.7% ^{11,12}
Х	х

Test Procedures —



Eligible Persons

Take2 Prophecy[™] Test for NPC is suitable for individuals who intend to do regular check-ups, who are asymptomatic and with suspected symptoms.

Disclaimer

Patients who have had organ transplant, currently have cancer or autoimmune diseases, or those currently receiving systemic glucocorticoid or immunosuppressive treatment are not recommended for early NPC detection using our test. Please consult healthcare professionals for more information

About Us

Take2 Health is a healthcare start-up built from Hong Kong SAR, China which explores, invents, and builds empowering platform to harness the power of biomedical sciences and informatics to deliver better healthcare solutions to individuals and communities with actionable information and results. Take2 Health aims to be a key driver that makes innovative healthcare inventions widely accessible to the public in China and across Asia.

References

- 1. "Nasopharyngeal Cancer." Centre for Health Protection, Department of Health, The Government of the Hong Kong Special Administrative Region, 2021, www.chp.gov.hk/en/healthtopics/content/25/54.html, accessed 23 July 2021.
- Bray, F., et al. "Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries." CA: A Cancer Journal for Clinicians, vol. 68, no. 6, 2018, pp. 394-424.
- . Hong Kong Cancer Registry. Hong Kong Hospital Authority, www3.ha.org.hk/cancereg/. Accessed 23 May 2021.
- 4. Overview of Hong Kong Cancer Statistics of 2018. Hong Kong Hospital Authority, October 2020.
- 5. Chan, K. C. Allen, et al. "Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer." New England Journal of Medicine, vol. 377, no. 6, 2017, pp. 513-22.
- 6. Ng, Wai Tong, et al. "Familial Nasopharyngeal Carcinoma in Hong Kong: Epidemiology and Implication in Screening." Familial Cancer, vol. 8, no. 2, 2009, pp. 103-08.
- 7. Chua, Melvin L. K., et al. "Nasopharyngeal Carcinoma." The Lancet, vol. 387, no. 10022, 2016, pp. 1012-24.
- 8. Vaughan, TL, et al. "Occupational Exposure to Formaldehyde and Wood Dust and Nasopharyngeal Carcinoma." Occupational and Environmental Medicine, vol. 57, no. 6, 2000, pp. 376-84.
- 9. Overview of Hong Kong Cancer Statistics of 2019. Hong Kong Hospital Authority, October 2021.
- 10. Lam, W. K. Jacky, et al. "Sequencing-Based Counting and Size Profiling of Plasma Epstein-Barr Virus DNA Enhance Population Screening of Nasopharyngeal Carcinoma." Proceedings of the National Academy of Sciences, vol. 115, no. 22, 2018, pp. E5115-24.
- 1. Chang, Kai-Ping, et al. "Complementary Serum Test of Antibodies to Epstein-Barr Virus Nuclear Antigen-1 and Early Antigen: A Possible Alternative for Primary Screening of Nasopharyngeal Carcinoma." Oral Oncology, vol. 44, no. 8, 2008, pp. 784–92.
- 12. Tay, Joshua K., et al. "Screening in Nasopharyngeal Carcinoma: Current Strategies and Future Directions." Current Otorhinolaryngology Reports, vol. 2, no. 1, 2013, pp. 1-7.

TAKE2 PROPHECY TEST FOR NASOPHARYNGEAL CANCER

Go Live Again – Sharing from NPC Survivor,

Cheung Tat Ming (Hong Kong actor)

at Ming: "The survival rate of early-stage NF

detecting cancer early!

Contact Us

- Ø Address: Unit D, 25/F, YHC Tower, 1 Sheung Yuet Road. Kowloon Bay, Hong Kong
- C General enquiry: (852) 3613 0536
- **WhatsApp:** (852) 5377 0823
- Email: customer.support@take2.health
- **Facebook:** Take2 Health
- Website: take2health.net

Book Now









Take2 Health 檢測服務概覽

選項一

Take2 Prophecy™ 早期鼻咽癌篩查

選項二

Take2 Prophecy™ 早期腫瘤指標檢驗套餐 套餐測試包括以下項目:

- Take2 Prophecy™ 早期鼻咽癌篩查
- AFP(肝臟腫瘤指標)
- CA19.9(胰臟腫瘤指標)
- CEA(大腸腫瘤指標)
- CA125(卵巢腫瘤指標)-只適用於女性
- CA15.3 (乳房腫瘤指標) 只適用於女性
- PSA, TOTAL (總前列腺癌抗原指數) 只適用於男性

聲明:Take2 Prophecy™ 早期鼻咽癌篩查以外的測試項目由與Take2 Health合作的 實驗室及醫療機構提供。

♥ 電話: (852) 3613 0536
▶ 電郵: customer.support@take2.health
● 網站: take2health.net



Take2 Health Testing Services

Option 1 Take2 Prophecy™ Test for NPC

Option 2 Take2 Prophecy™ Early Cancer Detection Package

Items included in the package:

- Take2 Prophecy[™] Test for NPC
- AFP (Liver cancer marker)
- CA19.9 (Pancreatic cancer marker)
- CEA (Colorectal cancer marker)
- CA125 (Ovary cancer marker) for women only
- CA15.3 (Breast cancer marker) for women only
- PSA, TOTAL (Prostate cancer marker) for men only

Disclaimer: Test items other than Take2 Prophecy™ Test for NPC are performed by Take2 Health's partnering laboratories and medical organisations.





TAKE2 PROPHECY^{**} 早期鼻咽癌篩查

GO 開展第二人生

其實香港鼻咽癌發病率是全球平均的5-6倍



鼻咽癌又稱「廣東癌」!

鼻咽癌在東南亞及南中國十分普遍,當中以在廣東、廣西和香澤 等地的發病率尤其高企;因此,它被俗稱為「廣東癌」。在本港 而言,它是十大常見癌症之一,每年有六百至八百多宗鼻咽癌 病例,更是過去十年間45-64歲男士五大癌症之一³,實在不容 忽視。

二十多歲女士都有機會患上*!

有鼻咽癌患者只是二十多歲的女士,所以它對年輕女士的影響也 不容忽視。根據真實個案分享,該名女士接受鼻咽癌治療後連日常 飲食都深受影響,痛楚難耐 *資料來源: "癌者治療後易出現口腔副作用,四成受訪者感口腔有鐵鏽味." HK01,11 May 2021.

「七老八十」才會患上? 逾8成鼻咽癌患者年齡低於65歲

2009-2018年香港鼻咽癌發病年齡分佈



頭痛、鼻塞,真的只是感冒嗎?

早期鼻咽癌病徵與感冒或炎症徵狀非常相似(如下圖所示), 故患者容易混淆病徵而延誤求診;數據顯示,80%患者在初診時



病徵因人而異,請向醫護人員了解更多。

家族病史是唯一患病因素? 除了家族病史⁶是高危因素,還要留意生活習慣及環境因素!



有吸煙習慣









威染Epstein-Barr Virus (EB病毒)



較多接觸甲醛或化學物品





每出現以上一項高危因素,患上鼻咽癌的風險將會顯著提高。

鼻咽癌雖不能「預防」,卻能「提防」

期鼻咽癌病徵不明顯而容易被忽略,加上目前尚沒有 j鼻咽癌的疫苗或特效藥,令此疾病看似防不勝防。 ð著醫學不斷進步,透過嶄新的早期鼻咽癌篩查技? E讓患者及早發現患病並接受治療,增加治癒機會及減 寮帶來的副作用,早期鼻咽癌患者的存活率更可高於

從使我們不能直接「預防」患癌,卻能「提防」癌症!

Take2 Prophecy™

Take2 Prophecy[™] 早期鼻咽癌篩查是一項突破性的無創早期鼻 咽癌篩查,透過簡單抽血,結合PCR及次世代DNA測序技術 (NGS: Next-generation Sequencing) 來檢驗血漿中帶有鼻咽 癌特徵的DNA,能有效識別出早期鼻咽癌患者,提高其成功治癒 的機會及存活率。



	Take2 Prophecy™ 早期鼻咽癌篩查
使用技術	PCR及NGS
檢驗項目	✔帶有鼻咽癌特徵的 DNA
假陽性率	√ 0.7% ¹⁰
靈敏度	√ >97% ^{5,10}
已通過大規模 臨床驗證 用於早期	√

醫生意見



	由香港中文大學團隊研發,應用次世代
研發	DNA測序技術於早期鼻咽癌篩查



假陽性率極低 (0.7%)



無需入院,抽血即可,過程簡單無創









#1)結果為陽性*,諮詢耳鼻喉科專家 2) 結果為陰性**,谁行年度檢查 * 陽性: 檢測到血漿中存在「人類和EB病毒的DNA與鼻咽癌相關之特徵」, 詳情請向醫護人員查詢。 ** 陰性: 檢測不到血漿中存在「人類和EB病毒的DNA與鼻咽癌相關之特徵」,詳情請向醫護人員查詢。

Take2 Prophecy™ 早期鼻咽癌篩查 與傳統EB病毒檢測方法有何不同?

傳統EB病毒 DNA測試	傳統EB病毒 血清學測試
聚合酶鏈式反應 (PCR)	酵素免疫分析法 (ELISA)
EB病毒DNA	EBV IgA-VCA 抗體
約3.4% ¹¹	可高達40% ^{11,12}
約81.4% ¹¹	42.9-92.7% ^{11,12}
Х	Х

`杳流我



適用人士

此篩查的適用群體包括:常規體檢者、無徵狀人士及有疑似 徵狀人士等。

免責聲明

此篩查<u>不建議</u>已經進行器官移植人士、已患有其他癌症、 自身免疫系統疾病、正接受全身性糖皮質激素及免疫抑制 治療的人士使用,詳情請向醫護人員查詢。

TAKE2 PROPHECY 早期鼻咽癌篩查

關於我們

Take2 Health是一家創始於中國香港的初創企業,致力於探 索、開發和建立開拓性的平台,以運用生物醫學信息學的力 量,為個人和社區提供更完善的醫療方案,讓大眾掌握可付 諸於行動的健康資訊及新科技應用和結果。Take2 Health的 目標是成為業內的倡導者,以推動創新醫療研發在中國乃至 整個亞洲廣泛應用。

參考資料

- 1. "Nasopharyngeal Cancer." Centre for Health Protection, Department of Health, The Government of the Hong Kong Special Administrative Region, 2021, www.chp.gov.hk/en/healthtopics/content/25/54.html, accessed 23 July 2021.
- 2. Bray, F., et al. "Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries." CA: A Cancer Journal for Clinicians, vol. 68, no. 6, 2018, pp. 394-424.
- 3. Hong Kong Cancer Registry. Hong Kong Hospital Authority, www3.ha.org.hk/cancereg/. Accessed 23 May 2021.
- 4. Overview of Hong Kong Cancer Statistics of 2018. Hong Kong Hospital Authority, October 2020.
- 5. Chan, K. C. Allen, et al. "Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer," New England Journal of Medicine, vol. 377, no. 6, 2017, pp. 513-22.
- 6. Ng, Wai Tong, et al. "Familial Nasopharyngeal Carcinoma in Hong Kong: Epidemiology and Implication in Screening." Familial Cancer, vol. 8, no. 2, 2009, pp. 103-08.
- 7. Chua, Melvin L. K., et al. "Nasopharyngeal Carcinoma." The Lancet, vol. 387, no. 10022, 2016, pp. 1012–24.
- 8. Vaughan, TL, et al. "Occupational Exposure to Formaldehyde and Wood Dust and Nasopharyngeal Carcinoma." Occupational and Environmental Medicine, vol. 57, no. 6, 2000, pp. 376-84.
- 9. Overview of Hong Kong Cancer Statistics of 2019. Hong Kong Hospital Authority, October 2021. 10. Lam, W. K. Jacky, et al. "Sequencing-Based Counting and Size Profiling of Plasma Epstein-Barr
- Virus DNA Enhance Population Screening of Nasopharyngeal Carcinoma." Proceedings of the National Academy of Sciences, vol. 115, no. 22, 2018, pp. E5115-24.
- 11. Chang, Kai-Ping, et al. "Complementary Serum Test of Antibodies to Epstein-Barr Virus Nuclear Antigen-1 and Early Antigen: A Possible Alternative for Primary Screening of Nasopharyngeal Carcinoma." Oral Oncology, vol. 44, no. 8, 2008, pp. 784–92.
- 12. Tay, Joshua K., et al. "Screening in Nasopharyngeal Carcinoma: Current Strategies and Future Directions." Current Otorhinolaryngology Reports, vol. 2, no. 1, 2013, pp. 1-7.

o Live Again <u>達明分享</u>

二人生及了解進行「早期鼻咽癌篩查」的重要性

聯絡我們

♥ 地址:香港九龍灣常悅道1號恩浩國際中心25樓D室

- 🔮 電話: (852) 3613 0536
- **O WhatsApp:** (852) 5377 0823
- ⊠ 電郵: customer.support@take2.health
- **Facebook:** Take2 Health
- 網站: take2health.net

立即預約





